TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04233385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Massage
Description: The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Touch
Description: Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
Study: NCT04646213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Cancer and Living Meaningfully (CALM) Therapy
Description: 6 sessions of individualized CALM therapy
Study: NCT03642548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifico
Description: Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
Study: NCT03207880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-level pregnancy test
Description: Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
Study: NCT03235388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit filters
Description: Institutional implementation of audit filters
Study: NCT02647177

Intervention type: OTHER
Intervention: Pancreatic Cyst Aspiration
Description: 10 CC of pancreatic cyst aspiration
Study: NCT01781325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBEHR
Description: physical therapy device to educate patients in physical therapy exercise performance
Study: NCT00803686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rsCT tablet
Description: On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Tablet
Description: Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rsCT tablet
Description: Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortical (rsCT) nasal spray
Description: Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
Study: NCT03936556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed toothpaste
Description: Marketed stannous fluoride (0.454%) toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marketed Cavity Protection Toothpaste
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Study: NCT04486339

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Stereotactic radiotherapy targets on the pulmonary vein ostium aiming to achieve pulmonary vein electrial isolation
Study: NCT01060618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maraviroc + Trofile ESTA® (diagnose test)
Description: The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
Study: NCT03500120

Intervention type: DIAGNOSTIC_TEST
Intervention: Seated saline infusion test
Description: Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge.

Intervention type: DIAGNOSTIC_TEST
Intervention: Seated saline infusion test
Description: Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge.
Study: NCT03448107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride (SDF)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Glass Ionomer Sealants (GC Fuji IX)
Study: NCT01820793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Description: proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
Study: NCT00949481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnancy Test
Description: Free pregnancy test strips will be supplied to family planning clinics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Job aid
Description: A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)
Study: NCT02372149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% intravenous immunoglobulin (IVIg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% intravenous immunoglobulin (IVIg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride
Study: NCT01366079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position change
Description: Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral
Description: In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
Study: NCT01263704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
Study: NCT00266877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Study: NCT02619773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mupirocin ointment
Description: Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
Study: NCT01263704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
Study: NCT02298101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: FEV1, FVC assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: FEV1, FVC assessment
Study: NCT00927485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcumin (Curcumin)
Description: Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcumin (Curcumin)
Description: Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
Study: NCT02548403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Study: NCT00927485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Factor Questionnaire
Description: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Risk Factor Questionnaire
Description: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
Study: NCT02548403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc with simethicone
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc with simethicone
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
Study: NCT04092751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA
Description: Single oral 20-mg dose of PRA on Day 1 AM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078 plus PRA
Description: Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
Study: NCT00832039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium-selenite
Description: An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium-selenite
Description: An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Procalcitonin guided therapy
Description: Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procalcitonin guided therapy
Description: Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.
Study: NCT00545285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Surgical implantation of specific hip replacement components for treatment of osteoarthritis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Surgical implantation of specific hip replacement components for treatment of osteoarthritis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Surgical implantation of specific hip replacement components for treatment of osteoarthritis
Study: NCT00927485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Three tubes of blood at visits 0, 4 and 12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Description: Three tubes of blood at visits 0, 4 and 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies (Sigmoidoscopy)
Description: Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Biopsies (Sigmoidoscopy)
Description: Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies (Upper endoscopy)
Description: Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Biopsies (Upper endoscopy)
Description: Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
Study: NCT02421861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Management in the ICU
Description: The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care (UC)
Description: The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.
Study: NCT02134600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 enriched fruit juice
Description: Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2.
Study: NCT03885297

Intervention type: DRUG
Intervention: Saxenda
Description: Obesity pharmacotherapy

Intervention type: OTHER
Intervention: Lifestyle modification
Description: Tier 3 NHS weight management

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Small molecule intermediates and products of metabolism

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA
Description: Small non-coding RNA molecules
Study: NCT00283010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational DVDs
Study: NCT01668277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.2% NaCl
Study: NCT00545285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Surgical implantation of specific hip replacement components for treatment of osteoarthritis
Study: NCT03422770

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test
Description: Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
Study: NCT01577290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered Mindfulness Training Program
Description: A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion group
Description: Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
Study: NCT03422770

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ECG and Holter-ECG
Description: ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ECG and Holter-ECG
Description: ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ECG and Holter-ECG
Description: ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 6 min walking test
Description: 6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 6 min walking test
Description: 6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 6 min walking test
Description: 6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.
Study: NCT02775357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement and communication of HIV risk
Description: Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV testing and counseling
Description: Participants received HIV testing and counseling following standard Ministry of Health guidelines